Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Generation Bio Co. (GBIO)
NASDAQ:GBIO
Holding GBIO?
Track your performance easily
GBIO Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.02 - $4.65
Previous Close$2.21
Volume130.36K
Average Volume (3M)98.88K
Market Cap
$147.50M
Enterprise Value$24.51M
Total Cash (Recent Filing)$216.94M
Total Debt (Recent Filing)$93.96M
Price to Earnings (P/E)―
Beta3.33
Next Earnings
Nov 07, 2024EPS Estimate
-$0.27Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.39
Shares Outstanding66,741,175
10 Day Avg. Volume79,149
30 Day Avg. Volume98,876
Standard Deviation0.31
R-Squared0.19
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.28
Price to Sales (P/S)11.20
Price to Cash Flow (P/CF)-1.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.86
Enterprise Value/Gross Profit4.15
Enterprise Value/Ebitda-0.19
Forecast
1Y Price Target
$8.00Price Target Upside270.37% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering5
Generation Bio News
PremiumCompany Announcements
Generation Bio Co. Ends Lease Citing Landlord BreachBulls Say, Bears Say
Bulls Say
Financial StabilityGeneration Bio reported a quarter-end cash balance of ~$217M, which supports operations into the second half of 2027, ensuring financial stability and continued development efforts.
Innovative TechnologyGeneration Bio's gene therapy platform shows increased cell specificity, lower immunogenicity, and dose-dependent protein expression, highlighting significant advancements in biotechnology.
Partnership MilestonesCollaboration with Moderna makes Generation eligible for up to $1.8B in milestone payments upon specified achievements.
Bears Say
Operating LossGeneration Bio reported a Q1 operating loss of $78M due to a one-time loss on the termination of their manufacturing facility lease of $57M.
Program Development TimelineAbsent a clear timeline to translation of a lead program into NHPs or an IND, the stock is maintained at a Market Perform rating.
Stock ValuationShares are seen as fairly valued at current levels based on a discounted cash flow analysis.
---
Ownership Overview
18.17% Insiders
24.67% Mutual Funds
0.37% Other Institutional Investors
49.46% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
GBIO FAQ
What was Generation Bio Co.’s price range in the past 12 months?
Generation Bio Co. lowest stock price was $1.02 and its highest was $4.65 in the past 12 months.
What is Generation Bio Co.’s market cap?
Currently, no data Available
When is Generation Bio Co.’s upcoming earnings report date?
Generation Bio Co.’s upcoming earnings report date is Nov 07, 2024 which is in 2 days.
How were Generation Bio Co.’s earnings last quarter?
Generation Bio Co. released its earnings results on Aug 07, 2024. The company reported -$0.31 earnings per share for the quarter, missing the consensus estimate of -$0.274 by -$0.036.
Is Generation Bio Co. overvalued?
According to Wall Street analysts Generation Bio Co.’s price is currently Undervalued.
Does Generation Bio Co. pay dividends?
Generation Bio Co. does not currently pay dividends.
What is Generation Bio Co.’s EPS estimate?
Generation Bio Co.’s EPS estimate is -$0.27.
How many shares outstanding does Generation Bio Co. have?
Generation Bio Co. has 66,741,170 shares outstanding.
What happened to Generation Bio Co.’s price movement after its last earnings report?
Generation Bio Co. reported an EPS of -$0.31 in its last earnings report, missing expectations of -$0.274. Following the earnings report the stock price went up 8.108%.
Which hedge fund is a major shareholder of Generation Bio Co.?
Among the largest hedge funds holding Generation Bio Co.’s share is Baker Bros Advisors LP. It holds Generation Bio Co.’s shares valued at 3M.
---
Generation Bio Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$8.00 (270.37% Upside)
$8.00 (270.37% Upside)
Hedge Fund Trend
Increased
By 835.7K Shares
Last Quarter.
Last Quarter.
Technicals
SMA
Negative
20 days / 200 days
Momentum
126.66%
12-Months-Change
Fundamentals
Return on Equity
-85.71%
Trailing 12-Months
Asset Growth
-34.48%
Trailing 12-Months
Company Description
Generation Bio Co.
Generation Bio Co is a genetics medicine company which is focused on creating gene therapies to provide durable and redosable treatments for patients suffering from rare and untreated diseases. The company focuses on liver and retina related diseases.
---
GBIO Stock 12 Month Forecast
Average Price Target
$8.00
▲(270.37% Upside)
Technical Analysis
Best Analysts Covering GBIO
1 Year
---